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INTRODUCTION 
There has been an increasing use of antibiotics in all 
areas of medicine. This has been associated with 
increasing resistance, both within, and now more 
worryingly, between drug classes, both in hospitals and 
in the community [1,2]. In the face of these develop- 
ments, it is of major concern that there have been no 
totally new classes of antibiotics with novel modes of 
action commercialized since 1961 [3]. In most infect- 
ions, the magnitude of the effect of resistance on patient 
outcomes is poorly understood [l], yet advertisements 
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in medical journals make fkequent use of resistance 
surveillance data, backing up the fear of failure. 
Promotion of new antibiotics by the pharmaceutical 
industry is proving effective in changing doctors' 
prescribing habits, h o s t  always h m  low-cost agents, 
such as penicillin or erythromycin, to high-cost agents, 
such as the newer cephalosporins, fluoroquinolones, 
and macrolides. 
Antibiotics are prime examples of mature pharma- 
ceutical products that have gone through the challenge 
of discovery and development as new agents to reach 
the far more complex phase of ensuring their use in the 
most effective manner, in the face of complacency 
based on their assumed effectiveness in reducing the 
morbidity and mortality of infectious disease [l]. 
Publication of this Special Article is funded by SmithKline 
Beecham Pharmaceuticals. 
The article has been subjected to the same peer review 
process regulating all published material in the journal. 
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Against ths  background, four challenges emerge: 
1. Infectious diseases continue to cause major 
morbidity and mortality. 
New and old antibiotics continue to be available for 
their treatment. Demands, beyond the rational, lead to 
their use when no benefit can be expected. Set against 
this there is very little understanding of the impact of 
resistance on the outcome of infection, especially in 
general practice. Proliferation of use, rational and 
indiscriminate alike, is linked to increasing resistance. 
Calls for more appropriate use h m  opinion leaders, 
academics, regulators, governments and the WHO 
have been largely ignored, since the impact of resistance 
at present is difficult to discern in individual patients in 
most clinical settings, as well as in the community as a 
whole. 
2. Antibiotic groups have overlapping anti- 
bacterial and clinical effects and so decision- 
making in relation to prescribing has become 
much more complex. 
For example, for the treatment of community-acquired 
pneumonia, a whole range of antibiotics is used, 
including penicillins and cephalosporins, macrolides, 
fluoroquinolones and even tetracyclines. The prescriber 
cannot determine his choice on the basis of clinical trial 
results, since these have rarely assessed differences in 
outcome. Furthermore, implications of the emergence 
of antibiotic resistance-increases in morbidity or 
mortahty, or the spread of resistance in the normal flora 
within hospitals and the community-have rarely been 
taken into account in clinical trials. Without data on 
the effect of antibiotics on patient outcomes, no 
prescriber can use antibiotics appropriately. 
3. Although there are more data collected in 
areas germane to the rational use of antibiotics, 
these are rarely available in forms usefhl to the 
prescriber. 
Databases exist which relate to bacterial genetics and 
physiology, modes of action of antibacterial substances, 
prevalence of resistance, prescribing patterns, health- 
care u h t i o n ,  demographics and even clinical outcome 
in individual cases. These databases are unconnected 
and the methods for connection have not been 
explored. 
4. There is an increasing tension arising from 
differences between individual patients’ and 
doctors’ desires and those of society at large. 
The potential threat to society of individual medical 
treatment decisions is more finely drawn in relation to 
antibiotic chemotherapy than in most other fields of 
medicine. Prescribing doctors are constantly urged to 
use antibiotics appropriately and prudently so as to 
optimize patients’ outcomes and minimize the acqui- 
sition and spread of antibiotic resistance [l]. But the 
evidence base expected to be derived h m  clinical trials 
usually fails to give them the guidance required to 
achieve this end. Indeed, risk assessment analyses have 
never been applied to evaluate the ecological impact of 
antibiotics in human populations or on the environ- 
ment. Unfortunately, many calls for appropriate use 
merely mean a non-specific reduction in use. 
The Brockham Group [l] concluded that in- 
creasing resistance is likely to have an adverse effect on 
outcomes in community respiratory tract infections. To 
manage t h i s ,  we need to measure the precise impact of 
the use of antibiotics on the prevalence of resistance, 
the effect of resistance on a range of clinical outcomes, 
and the effect of outcomes on costs. It follows that we 
need to know the effect of antibiotics on outcomes. 
Randomized, controlled, double-blind chical trials are 
ofprime importance among the appropriate tools avail- 
able to us and to the regulatory authorities whose 
responsibhty it is to approve the marketing of anti- 
biotics [4,5]. 
1 AIMS AND METHODS 
Experts h m  chical microbiology, infectious diseases, 
pediatrics, medical statistics, epidemiology, general 
practice, general medicine, regulatory agencies, clinical 
pharmacology, pharmacy, pharmacoeconomics, phar- 
maceutical medicine, and healthcare assessment, met in 
Witley Park, Surrey, UK, on 29-31 May 1998. The 
meeting chairmen were Richard Bax and Fernando 
Baquero. 
The aim of the meeting was to produce a consemus 
on the strengths and weaknesses of prospective clinical 
trials of antibiotics as currently conducted. Secondarily, 
the experts were to make suggestions as to how such 
trials might be improved, particularly in respect of their 
external validity (generalizability). 
Five syndicate groups, including a chairman and 
rapporteur, then met for four sessions of between one 
and one and a half hours to discuss in turn each of the 
following four questions: 
What are the strengths and weaknesses of antibiotic 
clinical trials (using the paradigm of community- 
acquired respiratory tract infection)? 
What do we need to know to define the role of an 
antibiotic currently in use and the value of individual 
prescribing decisions? 
What are the priorities among those using the results 
of clinical trials? 
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How should clinical trials of antibiotics be conducted 
in future? 
Each syndicate group then reported to the plenary 
group the findings of their discussions, which were 
then M e r  debated. This Report is the end product 
of this process. 
2 ANTIBIOTIC DRlELOPMENT PROGRAMS- 
CURRENT PRACTICE 
Although clinical trials of antibiotics to assess efficacy 
and de ty  are central to their introduction into clinical 
use, they form only one part of a complex, expensive 
process (Table 1) of discovering and assessing potential 
new antibiotic drugs. This process is aborted at an early 
stage for most compounds investigated, as they are 
found to be unsatisfactory in one way or another, but 
sometimes they are abandoned, after greater expense, 
Over the last 25 years, the conduct costs and 
complexity of antibiotic evaluation have increased 
exponentially. In 1977, the European file for intra- 
venous cefurolcime was produced at a cost per patient 
(including investigator grants and pathologic investi- 
gations) of appmxjmately A120, and at a total cost for 
the 900 patients included of around A1.5 million. In 
1981, the European file for cefotaxime, at a cost per 
patient of approximately A400, with about 3000 
patients, cost about A13.5 million. Around the year 
2000, the file for gedoxa&, a new oral quinolone, 
will include about 9000 patients costing about A5000 
each, at a total cost of about A45 million. Many other 
costs are incurred. It is considered that to develop a 
broad-spectrum agent fbm discovery to launch costs in 
the region of A1 billion. 
Has there been a parallel increase in the quality of 
the science of antibiotic evaluation, and a better under- 
standing of the benefits and drawbacks of antibiotic - 
at later stages 161. The few successfil agents have t i  bear , 
the costs of development of the many PI. 
use? Great advances are taking place in the discovery 
phase, as conventional methods of sneening fbr natural 
Table 1 The phases in the development of an antibiotic 
Phase Description 
Discovery and preclinical Synthesis of new drugs and chemical modification of old ones 
Increasing use of combinatorial chemistry 
Screening of biological material for antimimbial activity and molecular methods 
Drug chemistry, struchur-activity relationships, animal pharmacology, includmg toxicity t m  





Human phvrmcology in normal volunteers 
Phvrmcokinetics and p h c o d y n z m i n  
Drug interaction studies 
h4icrobiological studies, extended to resistance prevalence and mechanisms, susceptibility testing methods 
and their comparison, including zone size versus h4IC performance of quality-control strains, 
determination of tentative breakpoints 
Human pharmacology, including common unwanted &ects 
Initial mull (up to loo0 patients) prospective, randomized, comparative, blinded clinical trials aimed at 
Interactions, &em of organ impairment 
i n t e d  validity 
Further large trials (up to 100oO patients). includmg s p e d  groups to extend e x t e d  validity 
Compassionate use 
Collection of orgvlisms and susceptibility results b m  patients and relation to clinical outcome, to 
determine clinical, definitive breakpoint 
Analyses of trhl results, 'per protocol', 'intent to treat', subsets, etc. 
Extension of indications of use, including spedfic patient types 
Extension of comparisons with other licenced drugs. hoduct labeling based on reports on phases 1-111 
of phase I1 and 111 trials 
Post-licensing, fiuther clinical trials on groups of pa ti en^ identified on the basis of detection of M 
interactions or toxicity 
Survdllance of rrsistance 
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products are augmented, and even replaced, by new 
methods of synthesis and screening. However, we are 
concerned with compounds that come through the 
early phases of assessment, with promising pharmaco- 
logic and antibiotic properties-that is, largely with the 
current phases 11, I11 and IV of development. 
Acceptance of the modern randomized clinical 
trial occurred in the UK 51 years ago [S]. The Medical 
Research Council trial was carried out to determine 
whether a proposed new treatment, streptomycin for 
advanced tuberculosis, was sufficiently efficacious to 
warrant industrial production of the drug. Like all 
advances in medicine, randomized trials went through 
a slow period of initial acceptance. Many physicians did 
not like them because they implied the abandonment 
of clinical judgment. Doctors were also unhappy about 
the ethlcs of giving some patients inferior treatment. 
A further medical objection was that the research pro- 
tocols were too rigid and not clinically realistic [9,10]. 
Although these complaints were eventually counter- 
balanced by the perception of the many advantages of 
randomized clinical trials, the shortfalls can s t i l l  be 
appreciated today. At the same time, randomized 
controlled trials are firmly accepted as the standard for 
evaluating therapy despite the absence of comparative 
investigations with alternatives to show that they are 
indeed the appropriate standard. Cqnversely, some 
would argue that alternative methods to randomized 
controlled trials have been assessed and found to be 
inadequate [ 1 13. 
Randomized controlled trials of antibiotics face 
unique problems. Because of the nature of infection, 
patients are recruited to antibiotic trials empirically, 
before the microbiological results are available. Analysis 
primarily relates to those patients who fulfiu the 
requirements of the protocol. To counter the bias 
introduced by the exclusions, all patients who receive 
at least one dose of the study drug are included in an 
‘intent-to-treat’ analysis. A separate analysis is also made 
of ‘unevaluable’ patients who have not met protocol 
criteria. Furthermore, microbiological results, when 
they do become available, often define subsets of 
patients of specific interest. However, there will often 
be reservations as to whether they have been truly 
randomized, even when they emerge in statistically 
significant numbers. Randomization minimizes the 
effects of sources of variation. We do not require that 
patients be similar within groups but try to ensure that 
they do not di6er between groups. The within-group 
variation can be eliminated in normal clinical trials by 
stratification or analysis of co-variance, but neither of 
those techniques can easily be used in antibiotic trials 
because of the empirical nature of antibiotic treat- 
ment. 
It is 10 years since the BSAC Working Party on 
Clinical Trials of antibacterial agents published its 
recommendations [12]. Later, the Infectious Diseases 
Society of America (IDSA) revised and significantly 
updated general guidance on trial design and was 
sponsored by the Food and Drug Administration (FDA) 
[13]. The European Society for Clinical Microbiology 
and Infectious Diseases (ESCMID) also produced a 
report in harmony with those of the FDA [14]. The 
guidelines were never intended to be the final 
statement; nevertheless, they contributed much to the 
science of antimicrobial evaluation. 
What is needed is not for randomized controlled 
trials to be ignored or other methods to be considered 
inadequate, but rather a better description of the 
strengths and weaknesses of clinical trials and other 
methods, as well as a clear objective of extending the 
science and art of all methods. 
3 PURPOSE OF ANTIBIOTIC CLINICAL TRIAL 
3.1 To provide information 
While the patient is the end user, and regarded by all 
as the most important in the chain, there are certain 
important players without whom the drug will never 
reach the patient: 
The pharmaceutical company is essential, since it develops 
the compound and generates appropriate idorma- 
tion for 
regulatory agencies, who are responsible to 
politicians and the public for the safety, efficacy and 
prescribers, who must determine whether a given drug 
patients, after discussion with them of the evidence 
quality of the product, and for 
is appropriate for their individual 
supporting its use. 
The main objective of initial clinical trials, at least, is to 
provide the pharmaceutical company with sufficient 
information to persuade the regulatory authority that 
the drug is effective, safe and well produced. This gives 
the authorities a dominant role in determining the trial 
program required. 
Information needed includes pharmaceutical data 
(relating to the quality of the product), microbiological 
data (in vitro and in vivo), data on efficacy and safety 
for those to whom the drug is given, data on the 
epidemiology of infectious disease, and, increasingly, 
data on the effects on society of the drug’s use, 
including cost and the development of resistance. New 
. concepts such as models of resistance, precisely defining 
the burden of disease within communities and mathe- 
matically quantitated benefits of drug use for that 
community, are currently being developed [15,16]. 
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32 To provide microbiological and phannacologic data 
Clinical trials are usually designed to generate 
microbiological data, ideally d e w  the pathogen and 
its antibiotic susceptibility. However, because of the 
complexity of the relationship between parasite and 
host, it is often difficult to determine the relevance of 
the pathogen and its antibiotic susceptibility to the 
disease state of the patient. This does not mean that 
such data are irrelevant, but rather very difficult to 
assess. Thus compounds that are clearly superior 
microbiologically may be found to have no clinical 
advantage, except in cases in which the main deter- 
minant of the clinical outcome is antibacterial activity 
against the individual pathogen. While microbiological 
data are necessary in defining diseases in which a given 
drug might be usell, they are not sufficient. Other 
crucial information generated in clinical trials includes 
a broad spread of clinical outcomes data on the 
pharmacology of the antibiotic, and, increasingly, its 
pharmacokinetics and pharmacodynamics, related to 
the site of infection and severity of infection. 
3.3 To provide information on evolving efficacy and safety 
The major output of any clinical trial is the demon- 
stration that the drug is effective and safe. Before 
efficacy can be properly studied, it is necessary to have 
clear definitions of the diseases and the patient types for 
which the trial antibiotic will be used [17]. Such clarity 
has often been lacking, but definition was a major 
achievement of the recent clinical trial guidelines 
working parties [12-141. 
The situation is made more complex by the 
established approach to clinical trials-the reliance on 
comparison with a ‘standard’ drug. One might assume 
that such a drug had at some stage itselfbeen shown to 
be effective, ideally in comparison with a placebo, but 
this is h o s t  never the case. Indeed, studies versus 
placebos would usually be considered unethical. 
The effect of antibiotic resistance is often not 
assessed in trial analyses, because patients infected with 
organisms showing in vitro resistance to either anti- 
biotic are excluded. Nonetheless, the demonstration 
that a new drug is as good as a standard comparator, 
given that the etiologic agent is susceptible to both in 
vitro, is an important part of the assessment. 
$4 To faHill commercial need 
3.4.1 Recouping costs 
The cost of development of a new chemical entity up 
to the time of launch as a drug is approximately 
L600-1000 million, including the costs of fidure of 
other products. To recoup this, and to make a reason- 
able profit, pharmaceutical companies need peak annual 
sales of the new drug of at least A300 million. In order 
to determine whether this is likely, companies need to 
perform clinical trials on a large number of types of 
infection to verfi that their drug will perform s u 5 -  
ciently well. 
3.4.2 Early warning of failure 
Pharmaceutical companies need an early-warning 
system built into the program of assessment to reject 
drugs that are of doubtfid efficacy, have a very limited 
spectrum of activity, or are unsafe, before millions of 
pounds are spent fiuitlessly. As an example, d o x a c i n ,  
a new fluoroquinolone, was given in clinical trials to at 
least 13000 patients. After marketing, liver problems 
caused concern. The product has been withdrawn in 
the EU and severely restricted in the USA [18]. 
3.4.3 Awareness of a new compound 
Pharmaceutical companies use clinical studies as a 
means of raising awareness of a new compound and 
generating enthusiasm for it, in house or among 
potential users, for example by ensuring that opinion- 
formers are involved regardless of the usefdness of their 
contribution. 
3.4.4 Funding of research 
Many clinical scientists generate funds for the support 
of their academic departments which are important to 
their survival. 
3.5 To aid choice of antibiotics in clinical practice 
The clinical trial is the main source of information for 
the prescriber’s evidence base [19]. The randomized 
clinical trial is made up of the sample entered into the 
trial. This is defined in the protocol (inclusion and 
exclusion criteria). It is important to check that what 
is actually included in the clinical trial is what was 
specified in the protocol! The trial population should 
have some relevance to the general population. 
In the 1950s, when the first antibiotics were 
marketed, there was little competition and the pattern 
of infection was greatly different h m  what it is today. 
Thus the evidence required h m  risk-benefit analyses 
to just@ placing a drug on the market was much 
simpler. However, the answers to such questions as 
‘Does my patient need an antibiotic?’, ‘Which anti- 
biotic does my patient need and at what dose?’ or ‘For 
how long does my patient need treatment? are much the 
same now but are more complex, requiring the balancing 
of Werent ‘benefits’ against a diversity of ‘costs’. 
3.6 To measure the impact of antibiotic use on society 
3.6.1 Bacterial resistance 
Regulatory agencies have been predominantly interested 
in the development of resistance in vim and in the 
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pathogen afXecting the individual patient, and less in the 
effects on the normal flora or in long-term effects on 
the overall susceptibility of pathogens, or on bacteria in 
the environment It is assumed that antibiotic use will 
have an adverse effect on these. 
3.6.2 Impact of small differences between antibiotics 
Small differences may have a major impact ifpopula- 
tions of patients treated are very large. Such differences 
may be brought about not only in relation to 
parameters normally studied, but also in those less often 
studied such as compliance. The practice of ensuring 
equivalence with standard therapy may result in failure 
to detect such small but potentially clinically important 
differences. 
Phase 111 studies which show statistical equivalence 
to standard therapy also disallow the possibility of 
superiority. Unfortunately, it is this superiority that 
needs to be precisely defined in order to make effective 
prescribing decisions. If these small differences are 
important, we need to design trials to study them, as 
has happened with mortality, e.g. with lipid-lowering 
agents. The alternative is to set even tighter definitions 
of equivalence and not to accept wide ones. 
4 STRENGTHS AND WEAKNESSES OF PROSPECTIVE 
RANDOMIZED CLINICAL TRIALS 
4.1 Introduction 
The prospective, randomized, double-blind, com- 
parative clinical trial has become the familiar standard 
in drug evaluation. However, although because of its 
scientific basis it has widely acknowledged intrinsic 
strengths, it also has weaknesses that are not so widely 
recognized, particularly in the evaluation of antibiotic 
agents. Furthermore, when the indwidual clinician 
attempts to use its results, in the pursuit of the practice 
of evidence-based medicine, additional problems 
become apparent. The strengths and weaknesses, set 
out in Table 2, will now be discussed in detail. 
4 2  Concept 
The validity of the randomized controlled clinical trial 
as a scientific concept is one of its major strengths: 
1. In confirming scientific concepts, it minimizes 
bias on the part of the promoter of the trial, most often 
the manufacturer of the potential new product, on the 
part of those who conduct it, including the agents of 
the manufacturer, of those treating the patients, of the 
patients themselves, and of those who interpret the 
outcome. 
2. It also limits and renders transparent the effects 
of chance, thus contributing to the likelihood of 
detection of type I or I1 errors. Particularly important 
features are that the population to be studied is clearly 
defined, and that a starting point is identlfied in the 
study of each individual patient. 
3. Outcomes are varied, ranging &om clearly 
identifiable clinical or microbiological events to more 
subjective measures, and are amenable to statistical 
analysis, peer review and replication. 
4. Clinical trials are able to demonstrate superior 
efficacy, though they are often not designed to do so in 
practice. 
5. Their validity, arising h m  standardized method- 
ology, is such that results can be used in conjunction 
and comparison with those of similar trials, often in 
formal meta-analyses, to strengthen-r negate-con- 
fidence in their conclusions [lo]. Statisticians vary in 
the interpretation of internal validation. 
In the face of these undoubted strengths, a number 
of weaknesses have gradually become apparent: 
1. For many infections, it is considered unethical 
to perform a placebo-controlled trial for patients with 
moderate-to-severe bacterial infections. 
2. The randomization process can be applied only 
at the entry of a patient into a trial, whereas the specific 
infection for which randomization is actually required 
is often definitively diagnosed only after a f m  days, 
during which treatment will have necessarily begun. 
For example, in trials of the efficacy of antibiotics, 
patients with all forms of community-acquired pneu- 
monia can be randomized, including those with 
pneumococcal pneumonia, but the latter may turn out 
to be too few in number for any such randomization 
to produce scientifically valid data. Equally, many 
patients are excluded h m  analyses because the specific 
etiologic diagnosis is not made, but will be included in 
‘intent-to-treat’ analyses. Interest in further subsets of 
patients, e.g. with pneumonia caused by penicillin- 
resistant pneumococci, will again often result in there 
being very smalI  numbers of patients for analysis. 
3. Antibiotic trials are required by regulatory 
authorities to be designed to demonstrate equivalence 
in efficacy to that of a standard comparator, within 95% 
confidence intervals of 10-20% or sometimes 30%, 
depending on the established success rates of the 
comparator agents. This results in difficulties in 
application of their results to clinical practice, when the 
prescriber may want to know which is statistically 
sigdicantly the best drug overall. Alternatively, the 
prescriber can accept that neither is better when two 
treatments have been demonstrated to be equivalent, in 
whch case choice can be made using a criterion other 
than efficacy. Controlled analyses of equivalence trials 
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Can show di%mnce or establish equivalence 
Diminishes bias 
Diminishes bias 
Capable of *ur 
Short or long term possible 
Placebo or standard 
Pre-allocates treatment and so 
prevents organizer or clinician bias 
P-ts doctor-patient bias 
Internally valid 
Shows equivalence with standard in 
e&cacy and toxicity 
Good fix regismtion and mvketlng 
Comparative efficacy and tolerability 
known versus standard drug for 
average trial patient 
Con6rmation of S category 
Emergence of mistance in pathogen 
duringtrial 
Understand, thus empowered 
Some benefits and costs clarified 
Overemphasis on outcome as ‘truth’ in evidence- 
based medicine 
Alternative designs and analyses inhibited 
Usually designed for equivalence 
Possible only at entry 
Assumption of blinding not ahvys justi6ed in pracrice 
Costly, complex 
Short term only is the norm 
Placebo often unethical 
Standard not stan- 
Ofken not possible for specific indication; can be 
subverted; may fail because of case mix 
Can be subverted by doctor or patimt 
Externally less valid or invalid 
Poorly predictive for individual pmcribiug decisions 
M y ,  no standard available 
No information on rare, unwanted effects 
Marketing limited by lack of demon&don 
of superiority 
Extrapolation to real patients di&cult/imposrible 
Standard not stan- 
True benefit compved with placebo o h  not known 
No clinical establishment of R breakpoint 
Often, mauy microbiologically uncvaluable parimtr 
No i n f o d o n  on long-term epidemiology 
Can disrupt, to disadvantage offuture patients 
True financial and non-finanad costs sddom 
determined 
are possible but, clearly, proof of competence of a trial 
is not delivered [ZO]. This is not truly a problem of 
principle: trials can be designed to show superiority, 
but they are inevitably larger, ofien more complex and 
always more expensive, and are attempted idkquently. 
4. The assumption that the trial process can be 
blinded with complete confidence is ofien unwarranted: 
patients and their doctors are ofien able to detect 
difkences between two drugs being compared, such as 
taste or texture, and modify their responses accordingly 
In addition, the methodology cannot be used to 
compare a patient’s subjective response to Merent 
regimens of therapy when it is the subjective qualities 
of the regimen that require study: a dosage regimen 
involving injection cannot be compared with one 
involving oral administration, or one consisting of 
once-a-day administration with one of four times a day, 
since the patient cannot be blinded to what is to be 
assessed. Theoretically, these studies can be blinded 
using double-dummy techniques, but the additional 
placebo injections are usually considered inappropriate. 
The success or otherwise of this technique for intra- 
venous formulations has not been studied. Alternatively, 
the evaluator is ‘blinded’. 
5. In all clinical trials there is the problem of 
applying the results for the ‘average’ trial subjects to the 
treatment of individual patients, even when the 
individual patient complies with all the entry criteria 
for the trial. This must be coupled with the additional 
ditKculties of extrapolation outside the defined circum- 
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stances of the trial. Selected outcomes of an average 
patient may not be pertinent for all outcomes, and this 
has effects that must be noted within clinical subgroups 
when the physician makes therapeutic decisions for 
individual patients in 0rdnxu-y clinical practice. The 
goal of showing average efficacy has led to the develop- 
ment of a statistical hegemony that dominates the 
current approach to designing and analyzing the results 
of randomized trials. 
6.  Statistical work conducted by the pharma- 
ceutical industry for regulatory approval is dictated by 
guidehes but shows a generally high number of short- 
comings, which include a poor understanding of areas 
of known statistical disagreements, unsatisfactory use of 
newer techniques and inadequacies in reporting [21]. 
7. Randomized controlled clinical trials are 
conducted to allow scientific information to be 
generated in such a way that intentional and non- 
intentional bias is minimized. The many potential 
sources of bias in designing, conducting and evaluating 
trials have been enumerated, and these must be taken 
into account in future. 
Two addtional points deserve attention, as follows: 
1. Invented here-the original discoverers of new 
technology are very anxious that a niche is found for 
their particular product. This ‘invented here’ mentality 
generates considerable enthusiasm. . Equally, it is 
recognized that those not involved in early research and 
development, but who take over the product at a later 
stage, can be sceptical or even antagonistic, and 
excluded fiom the enthusiasm. Both are powerful 
sources of potential bias in scientific design, conduct 
and evaluation. 
2. Funding-financial considerations can be a 
source of bias, both for those giving and receiving 
research funding within a company, and for those 
carrying out and regulating clinical trials. There is 
pressure to design trials that show the company’s 
product in the best possible light within the constraints 
imposed by regulatory authorities. Regulatory autho- 
rities will need to recognize these types of bias, and 
some already require companies to iden+ risk factors 
for failure which will then be incorporated into the 
trial analysis. It is often &cult to iden+ those with 
the potential to respond at the beginning of therapy, but 
ifrisk factors were known, the population entering the 
trial could be enriched by or confined to those who do 
have this potential. For example, in acute exacerbations 
of chronic bronchitis, only patients with the complete 
exacerbation symptom triad (increased dyspnea, 
sputum volume and sputum purulence) are known to 
benefit h m  antibiotic therapy. Inclusion of exacer- 
bations with lesser evidence of bacterial infection in 
clinical trials devalues comparisons. Both trial agents 
and either comparator or placebo arms may show 
‘efficacy’, as spontaneous resolution is the rule. 
Converselx patients with defked exacerbations may be 
sufficiently diluted by others for real benefits to be 
obscured. Therefore, trials with particular, severity- 
defined target populations and specifically excluding all 
others are required. 
Despite reservations, clinical trial methodology has 
been widely accepted as the only true assessment. This 
has inhibited the search either for improvements, for 
complementary studies or for alternatives-for research 
on research methodology. Research workers now often 
feel themselves to be reduced to the s t a t u s  of testers. 
4.3 Design 
In this context, it should be remembered that many 
drugs required to be used as standards by regulatory 
authorities have never themselves been subjected to 
comparative processes, and some are widely held not to 
work at all in some infections for which they are 
standard therapy! Icelandic [22] and Dutch experience 
with acute otitis media, showing as good long-term 
outcomes when only 20-30% of children are given 
antibiotics as in other countries in which over 90% are, 
suggests that such conclusions should be reconsidered. 
Even if a standard antibiotic had once been shown to 
be effective, changes in etiology, the evolution of 
antibiotic resistance, or changes in aected populations, 
might have rendered it ineffective, but undetectably so 
in conditions in whlch antibiotic use is not the only or 
main determinant of outcome. 
The assiduous company which carries out trials on 
patients who are likely to be able to show benefit might 
find itselfwith a very limited licence while established 
drugs of no greater usefulness continue to have broad 
indications. Regulatory constraints are a weakness 
when, even appropriately, they confine a company to 
indications for patients included in the protocol, but 
allow other companies already holding licences for 
similar products to continue marketing outside these 
confines. For example, a compay with a drug that 
might be usell in treating otitis media could be ill- 
advised to conduct a perfectly rational trial on children 
aged under 2 years (the only ones likely to benefit h m  
antibiotic therapy), since it would be allowed to 
recommend treatment only for children under 2 years 
old, while their competitors with an old licence would 
have an indication (almost certainly inappropriate on 
the basis of current knowledge) for all ages. This is a 
problem also for other areas of medicine. The over- 
simplification of the complex may be regretted fiom a 
scientific viewpoint but may have essential commercial 
rewards. It is also clear that the pursuit of equivalence 
might ignore true superiority in practice, to the 
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detriment of the patient. All this may be more or less 
obvious to experts, but not necessarily to non-specialist 
medical practitioners. 
The use of increasingly complex case-record forms, 
introduced to ensure that the clinical trial answers as 
wide a range of questions as possible, may be counter- 
productive. They are difficult to analyze, and may 
generate confusing information. It is not known 
whether this increase in complexity (in which pharma- 
ceutical companies have been very successll) increases 
scientific robustness, but it certainly increases costs 
(which companies seem unable to conml). There may 
be a case for only the major questions to be answered 
by large trials with simple record forms, leaving other 
questions to be answered in Werent ways. 
Although clinical trials will detect common un- 
wanted effects, such as a relatively high incidence of 
diarrhea, or drug interactions, they will not detect rare 
toxicity or interactions. It is of interest that such effects 
have led to the withdrawal of a number of drugs after 
marketing. Antibiotics are no excepti0n-e.g. cephalo- 
ridine, tedoxacin and most recently trovafloxacin 
Although there is no intrinsic reason for it, clinical 
trials commonly cover only the short term of a parti- 
cular episode of infection. They do not, for example, 
examine effects on quality of life or the effects of a 
given course of treatment on subsequent episodes of 
acute or chronic bronchitis or of acute otitis media. 
Short-term clinical trials may therefore underestimate 
benefit. For similar reasons, they do not often assess the 
impact on the emergence of antibiotic resistance in 
pathogens or normal flora, on a demographic basis, or 
the true financial cost. 
81 * 
4.4 Conduct 
The trial design imposes standards on those who 
conduct them, so that they are authoritative h m  
a practical as well as a theoretical viewpoint. Clinical 
research trial programs are designed by pharmaceutical 
companies guided by regulatory authorities and advised 
by academics, but they are increasingly conducted by 
clinical research organizations. It is possible that the loss 
of contact between those actually treating trial patients 
and those who will receive and evaluate their results 
might result in signrficant losses of valuable information 
not directly required h m  the trial design. Further- 
more, since contract research organizations have a 
contractual obligation, they recruit patients, often in 
large numbers, over short periods of tim-d, 
indeed, drugs are now being registered in record time 
with record numbers of patients. Although outright 
ftaud is probably rare but not impossible [23], minor 
but repeated violations of protocol may not be. There 
is a particular need for adequate statistical approaches 
to between-center variations in large multicenter trials. 
It is normal and common for the promoter of a 
trial to seek to show a new drug in the best possible 
light. This may involve the inclusion of patients with 
high probability of spontaneous cure during the study 
period, so that the trial is overwhelmed by patients 
unlikely to show any effects of either standard or 
experimental drug. It is now clear, for example, that 
many patients with acute exacerbations of chronic 
bronchitis will not benefit from antibiotics, either 
because the contribution of infection to their disease 
state is minimal (or, at the other end of the spectrum, 
overwhelming) or it is due to an infective agent, namely 
a virus, that is not susceptible to antibacterial therapy. 
When such patients are in a majority, it is not surprising 
that it is difhcult to demonstrate benefit, or to 
Werentiate the outcome for patients infected with 
susceptible or resistant bacteria [24]. Similarly, in 
controlled studies in otitis media, drugs with excellent 
activity will appear less efficacious than they really are 
and drugs with poor antibacterial activity will appear 
more efficacious than they really are-the so-called 
‘Polyanna phenomenon’ [25]. 
The discretion allowed to the doctor to exclude a 
patient or individuals h r n  a trial-for medical or social 
reasons that would not lead to exclusion by protocol- 
is essential, but can easily introduce further bias. This 
discretion is further exercised by the clinician when it 
is found that the patient is infected with resistant 
organisms, when there is an option to continue 
obviously effective therapy or to withdraw the patient. 
Again, this is entirely reasonable, but it results in a 
virtual inability to directly assess the clinical importance 
of microbiological resistance. It also prevents the 
establishment of the clinical validity of resistance 
breakpoints determined on the basis of microbiological 
and pharmacokinetic and pharmacodynamic pan- 
meters. 
Good clinical practice (GCP) covers education and 
training of s t a E  and allows regulators to inspect 
investigators and sites for major clinical trials as well as 
the pharmaceutical companies. Hawever, much more 
careful audit of what actually happened versus what was 
expected to happen is needed. Surely, recruiting an 
average of 5-10 patients per center in lo00 centers is 
different fbm recruiting 50-100 patients in 100 centers? 
4.5 Interpretation 
4.5.1 Internal validity of clinical biels 
Clinical trials are designed to be internally valid, so that 
another researcher conducting the same trial will get a 
similar answer. A demonstration of internal validity is 
used to demonstrate that the data generated are 
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believable. Much of this validity depends on the criteria 
for inclusion in the trial-d exclusion h m  it. The 
tighter the actual (as opposed to the planned) similarity 
between the populations sampled, the greater will be 
the reproducibility. For example, if the trial entry 
criteria stipulate an age range of 15-65 years, but the 
sample entered is aged 25-40 years, then the results of 
the trial apply only to the latter p u p .  Generalization 
of the trial results to the intended population (i.e. age 
15-65 years) is not just a matter of extending the age 
range but of broadening the complete set of charac- 
teristics of the trial patients. No matter how large a 
randomized clinical trial may be, it is never going to 
include all possible combinations of characteristics. The 
use of the clearest and most reasonable inclusion criteria 
may help to ensure internal validity. However, with 
limited patient entry, the external validity for the actual 
patient population is low. 
4.5.2 Ekternal validity of clinical trials 
External validity is defined as the need in initial clinical 
trials to enter as homogeneous a population as possible, 
so that equivalence or superiority to a standard can be 
demonstrated. However, the purpose of the entire 
clinical trial program is also to predict how the 
antibiotic will perform in clinical practice, but since 
many clinically relevant variables are often eliminated, 
it may be di&cult to achieve this external validity. Thus 
the entry into phase I11 trials has moved away &om 
homogeneous samples, and it is now appreciated that 
the trials should enter as heterogeneous a sample as 
possible. The point is that we cannot study hetero- 
genicity by deliberately excludmg it. It is often noticed 
that patients in clinical trials respond differently h m  
those not in trials-the Hawthorne effect [26]. 
In addition, conditions which lead to exclusions 
h m  the clinical trial, e.g. concurrent illness or the 
administration of other drugs, commonly affect patients 
in the community. Multiple courses of therapy, and 
problems with compliance, both common in real Ee, 
are seldom assessed. The effect of the regulatory 
requirement that a given trial may or may not be 
conducted in a given country is another source of 
limitation of external validity. There is a notable lack of 
theory to accommodate these problems, but it is feared 
that the necessary increase in complexity may not be 
matched by an overall advance in interpretability. 
4.5.3 Types of validity 
Trials attempt to minimize all sources of variation other 
than those due to treatment, but they do so without 
fully resolving issues of internal validity (such as 
selection biases), and at the cost of external vahdity, the 
extent to which results can be generalized or extended 
beyond the conditions of the trial. In fact, it is necessary 
to consider five types of validity [27]. These are: 
criterion validity-does the outcome measured 
reflect the true state of the patient? 
construct validity-how well does the trial measure 
what it is supposed to (the outcome)? 
content validity-are the choice and content of the 
outcome measure appropriate for the purpose? 
face validity-is the method of aggregation to pro- 
duce a score or index sensible? 
discriminative validity-is the trial able to detect the 
smallest important clinically sigmfkant differences 
between treatment groups? 
Validations may be performed either before, during or 
after a clinical trial process, and the terms prospective, 
simultaneous and retrospective validation are used to 
describe these processes. Some investigators, such as 
Remington, have believed that extremely large c h c a l  
trials wiU validate themselves [28], but this is held now 
not to be true. Assumptions ofvalidq may lead to years 
of use of results without chdenge. 
4.6 Application of results 
To be approved, new therapeutic agents require 
unbiased, well-conducted, randomized trials. Conse- 
quently, statistical and design principles were used to 
establish a set of demands and requirements that would 
presumably provide the unbiased evidence. These 
demands include rigorous efficient criteria for admission, 
the use of standard dosing regimens, appropriate 
patients and randomization, a reliance on high-quality 
data, the use of double-blind observation, the develop- 
ment of intention-to-treat (ITT) analysis and the 
concepts of sample sizes to detect clinical significance. 
The statistical principles result in demonstrating the 
average efficacy of treatment with confidence. Clinical 
trials on antibiotics have evolved so as to yield 
information on safety and e&cacy which is of most use 
to regulatory authorities, including the standard as well 
as the new drug, and in this they are apparently 
successfid, since there is little impetus h m  such 
authorities for change. 
They also generate information that can be used 
to great effect by those who market the registered 
product, although the demonstration of equivalence 
with standard treatment rather than superiority is a 
limitation that drives them back to properties 
established before the clinical trial in phase I and I1 
assessments, e.g. spectrum and improved pharmaco- 
kinetics. Enthusiasm generated during the early phases 
of a drug’s assessment is thus often dampened, some 
might say realistically, by the results of clinical trials. 
Whatever the balance, the results of clinical trials are 
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widely used by marketing departments of pharma- 
ceutical firms to help clinicians decide on their treat- 
ment strategies. 
Other potential users of information derived from 
clinical trials of antibiotics are less well served. The 
practice of demonstrating equivalence, as approved by 
regulatory authorities, gives results which are of limited 
use to the prescribing doctor, who really wishes to 
know whether a new drug is superior to the current 
standard, particularly if there is a suspicion that the 
standard does not work well. In addition, equivalence 
studies can be thought of as second rate, as proof of 
competence of the trial is not delivered [23]. The 
physician will also wish to know how the new and old 
drugs deal with pathogens that are resistant in vitro, if 
they do not make the common but unwarranted 
inference that microbiological/pharmacokinetic resist- 
ance equates with antibiotic failure clinically, but will 
gain no information on this topic. 
A knowledge of short-term complications, neces- 
sarily of little risk to the patient’s eventual wellbeing, 
since otherwise the drug would not have been licensed, 
will not reassure them about rare unwanted effects and 
interactions, particularly in their real-Me patients. In 
relation to these patients, it will often be helpful if the 
trial has been limited to patients with the identical 
illness-say pneumococcal pneumonia rather than 
community-acquired pneumonia-but the diEiculties 
in such a trial design have already been mentioued. 
In theory, at least; clinical trials have the potential 
to assist medical education, but their limitations are 
oflen not recognized by those who attempt to impose 
the practice of evidence-based medicine, largely on the 
basis of published, peer-reviewed studies. For the 
Cochrane group, it oflen seems that the quality of a 
meta-analysis is more important than whether detailed 
trial designs had led to irrelevance to real patients. 
Clinically relevant meta-analysis relies on initially 
adequate data. 
The practice of conducting clinical trials under the 
aegis of clinical scientists working in hospitals provides 
much-needed funds for the beleaguered science of 
clinical research. Valuable parnerships between industry 
and academia have resulted. However, there has been 
less control of competence in spite of considerable 
efforts to produce good clinical research practice guide- 
lines. 
Potential patients may be well served by the 
prosiective, randomized, blind clinical trial, since an 
understanding of the simple principles of the trial will 
raise their status in the process of concordance which 
is replacing that of compliance in the doctor-patient 
relationship, and thus empowers them to make 
informed contributions to their own management. The 
industry and prescriber must not uncritically promote 
the evidence gained h m  randomized, controlled 
clinical trials [29]. However, successfully bridging the 
barriers between appropriate research evidence and 
clinical decision-making is needed [30]. 
outcomes can 
be used to devise further trials, assessing areas of 
importance not previously recognized or not measured, 
such as s m a l l  Merences in relation to very common 
diseases like acute otitis media, and particufarly in 
assessing more appropriate outcome variables. They 
also facilitate statistical and mathematical modeling. 
To those who design dinical 
5 FACTORS IN THE DESIGN AND INTERPRETATlON OF 
THE CUNICAL TRlALS OF THE FUNRE 
5.1 Sources of information 
Prescriber and patient have a variety of potential 
sources of information derived from clinical trials, 
which need to be considered as part of the trial 
planning process. Package inserts contain more and 
more information derived fiom clinical trials aimed at 
the prescriber and at the patient. Howwer, prescribers 
usually prefer to believe what is published in peer- 
reviewed journals rather than information provided in 
data sheets, despite the fact that this too has been 
reviewed, often more stringently, by trained assessors 
and external experts for the regulatory authority, and 
based on findings often made public in great detail. 
Local clinical guidelines are prepared by local formulary 
committees and aim to take account of local circum- 
stances: the level of knowledge within such groups is 
very variable and the interplay of prejudice is not always 
appreciated. The prescriber seldom sees the whole 
perspective, and indeed might well be overwhelmed 
by it, but greater knowledge of the pitfalls of clinical 
trial design (including an appreciation of the problems 
of comparison with a standard-ee above) and 
execution might help them to derive more robust 
information. 
52 Changes in society 
Society’s approach to health care has changed. There is 
greater interest in the risks rather than the benefits of 
antibiotic therapy, though this is complicated by the 
expectation that the benefits can s t i l l  be delivered 
without risk. The true total effect of antibiotic therapy 
is rarely studied in clinical trials, either for the medium 
to longer term in patients or in relation to the spread 
of organisms and resistance. These will need to be 
included in future. Furthermore, the concept of 
patients as customers whose views should be taken into 
account needs to be developed in clinical research. 
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5.3 The prescriber 
The personality of the prescriber is one of the main 
determinants of implementation of new treatments, 
and needs to be taken into account. Prescribers, like all 
of us, may be divided into risk-takers and risk-avoiders. 
There are also high- and low-risk products; a new 
intravenous product for the treatment of meningitis 
would be in the former category, while an oral 
antibiotic belonging to a familiar class would belong to 
the latter. Low-risk prescribers do not use high-risk 
products until they have been well established, whereas 
high-risk prescribers will do so, but will also be least 
consistent because they will readily move on to the next 
new product. Such fickle prescribers have their role as 
opinion-leaders, perhaps helping to sh f i  practitioners 
fiom prescribing drugs that, while doing little harm, 
may also do little good. 
6 WHAT INFORMATION DOES THE PRESCRIBER NEED? 
There are many sources of guidance on the rational use 
of antibiotics for individual patients; the details do not 
concern us here. However, all depend on a series of 
requirements: (1) that the partidar patient belongs to 
a group that is likely to show benefit fiom antibiotic 
therapy; (2) that choice of a specific agent will be 
guided by (a) inferred or individually available micro- 
biological results (does the antibiotic to be used inhibit 
the organism causing or likely to be causing the 
infection?), (b) antibiotic pharmacology (are the 
pharmacokinetic and pharmacodynamic properties 
appropriate, or, more simply, does the agent to be used 
reach the site of infection and is it bactericidal or 
bacteriostatic, and is the patient likely to be harmed?), 
and (c) clinical experience, increasingly to be based on 
validated evidence; and (3) the agent chosen will be of 
maximum cost-effectiveness. It is expected that many 
of the answers to the questions implied h m  these 
requirements wiu come h m  well-conducted, validated 
clinical trials-the major basis of evidence-based 
medicine. However, fiom the previous discussion, it is 
possible- to appreciate to what extent relevant evidence 
is available to the prescriber for the individual patient. 
The answer, in many cases, is very little! 
It is our belief that thu state of &iin can be 
remedied if we are willing to consider, devise and 
implement rahcal changes to the processes of trial that 
we have described. 
7 THE ASSESSMENT OF ANTIBIOTIC AGENTS 
PROPOSALS FOR THE FUTURE 
7.1 General recommendations 
The need for future assessment of new antibiotics, to 
address much more the needs of those who treat 
patients as well as those who produce antibiotics and 
approve them for use, has been emphasized throughout. 
To this end, there should be a return to a direct 
relationship between those who are developing the 
drug-usually a team fiom the relevant research and 
development group of the pharmaceutical firm-nd 
those who are treating the patients-the clinical 
academics. Neither should act alone. Erosion of this 
relationship has led to the all-too-fi-equent inadequacy 
of current trials, at least in relation to some of those 
who seek to use their results, particularly in trials which 
have involved many centers in different parts of the 
world. Trials should also be planned with the needs of 
the regulators M y  considered, including their need to 
satisfy the general public as well as the guardians of 
public health; t h i s  should be ensured by their continued 
involvement at the planning stage. 
72 Proposals for program design and interpretation 
The assessment of the new antibiotic of the fiture 
might well include well-conducted comparative trials, 
but the strengths of smaller, well-dsrected, non- 
comparative studies on patients who are likely to be 
able to validate surrogate markers of antibiotic therapy, 
such as pharmacokinetic/pharmacodynamic relation- 
ships, should not be neglected. Assessments based only 
on patients who are likely to show benefit should 
not lead to punitive restrictions in indications 
(labeling), in contrast to those based on the inclusion 
of patients in equivalence trials who are unlikely to 
show benefit. 
A reappraisal of the assessment process is vital, since 
major finds have already been given to groups whose 
interests are directed towards cost-effective health gain 
for the community at large rather than towards the 
needs of individual patients and those who treat them. 
The conclusion of the members of the symposium 
(Table 3) is that the early phases of development of a 
new antibiotic drug (taking as a model a drug intended 
for use against respiratory tract infections) should 
include intensive pharmacodynamic modeling (in vitro 
and animal, using human pharmacokinetics), to be 
followed by small-scale intensive studies on patients, 
and then, after limited approval for marketing, by well- 
directed comparative studies. This should not be used 
without fkther consideration for antibiotics with 
relatively poor activity or for the totally novel antibiotic 
classes, e.g. oxazolidinones. The process might flow as 
follows: 
7.2.1 Phases I and II 
These might be much as at present. Phase I1 studies 
should concentrate on modeling &om in vitro, animal 
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experiments, and phase I results should be related to the 
clinical indications intended. 
7.2.2 Phase lllA 
This phase should include at least one intensive, open 
study, although a comparative study might be appro- 
priate in some circumstances, e.g. when the standard 
drugs are not of established efficacy It is noted that there 
is a precedent for FDA acceptability of open studies 
when no adequate standard drug exists for comparison. 
Studies should be conducted in well-funded, 
accredited clinical centers, in direct partnership between 
clinical academics and the relevant, appropriately 
experienced experts from the pharmaceutical company 
team. The involvement of intermediaries is strongly 
discouraged. 
The patients recruited to the study should be 
capable of benefiting from antibiotic therapy, and 
should be around 50 in number (qnd certainly not more 
than 100). They should be chosen to represent well- 
defined and appropriate clinical or microbiological 
niches, such as pneumonia or acute otitis media caused 
by penicillin-susceptible and -mistant pneumococci. It 
was noted that t h i s  would necessitate the use of rapid, 
probe-based methods of diagnosis. 
Studies should be dynamic, including fkquent 
assessment of clinical condition, clinical laboratory 
measurements including concentrations of inflam- 
matory markers and mediators, phannacokinetic and 
pharmacodynamic parameters, microbial load and 
microbial antibiotic susceptibility. A scoring system 
representing responses must be developed, validated 
and used by investigators. New outcome measures that 
integrate clinical, microbiological, quality-of-life and 
economic outcomes are needed. Vdidation of some 
scoring systems is complex and may require large 
amounts of data. As a result of these intensive 
investigations, the time course of response to the new 
(and possibly to standard) drugs would be established. 
It is hoped that intensive s t u d y  of fewer patients will 
lead to much more precise information on the 
antibacterial effects of new compounds. 
Table 3 The proposal for a new type of assessment of a new antimicrobial agent 
Phase I (as at present) 
Phase II-rncaCy 
In vim and animal models, with human pharmacokinedcs 
Intensive open study, conducted by accredited investigators in collaboration with relevant team fbm p h c c u t i c a l  H o p e r s ,  in 
Consultation with rqimation authorities 
S d  scale (5C-100 patients) 
Patien6 who arc able to show benefit fbm antibiotic therapy 
Dynamic and detziled study of clinical progrrss, laboratory parameters, microbial load antibiotic susceptibility 
Phumzcokinetic/phumacodynvnic ass-ent 
Assessment based on validated scoring system 
Possibly small-scale randomized control trials related to specific indications with pharmacokinetic/phumzcodynvnic 
Phase IIIA 
Successhrl completion m k e d  by provisional rrgistntion, possibly in a specific geographic area 
szfery WMSmMt 
Phase 115-Sdety and further efficacy 
Pmspectivc controlled trial, conducted by accredited iwestigato~ in conjunction with relevant team fbm phurmccuticd devclopez 
in consultation with registration authorities 
Designed to show superiority of &ucy in at lust one uc;l or no inferiority with better adverse event profile or better convcnic~ce: 
SatifiCd 
Allocation biased in numbers towards new drug 
Rdevant validated outcome measures 
P ~ c o e c o n o m i c  studies 
Successful completion marked by full registration 
Phzpe N-Societal and d e t y  
Open long-term study linked to health-related databases, to establish: 
Incidence of unwanted events, including rare toxicity and drug interactions 
Effects on epidemiology of pathogenic and commensal orgulisms, antibiotic resisonce 
Concordance 
Cost-benefit for hcalthurc pwchasas 
Societll dfiucy and safc ty - - r~~~&~~ needed to trut, cost p a  response 
Succersll completion linked to reregisration 
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If the new drug shows efficacy in this phase, it 
should be granted provisional registration. It is noted 
that the FDA has used a ‘fast-track‘ system for certain 
drugs, such as products for the treatment of HIV 
disease. This provisional registration could include use 
in a certain geographic area or for specialists only, 
provided that data are available with whlch to assess 
safety, efficacy and effectiveness. We need to give more 
consideration to these provisional registration proposals. 
We do not want to perpetuate oligarchies of experts who 
might unduly delay the introduction of useful agents. 
7.2.3 Phase Ill6 
At this juncture there may be a place for one well- 
conducted prospective, randomized, comparative trial 
for each specific indication. The ratio of allocation to 
study drug versus standard drug might be biased 
towards the former, in a ratio of say 3:2, and valid 
stratification methods should be devised and used. 
Outcome measures should be relevant to c h c a l  
use, and might include speed of recovery, and, when 
appropriate, the more radical approach of patient- 
determined duration of therapy. They should also 
include longer-term full cost analyses, and impact on 
the community (financial and non-financial). There 
should be in place good arrangements for data capture 
and data processing. 
Endpoints should include the capdcity to demon- 
strate superiority of efficacy for specific indications 
where relevant. We recognize the difl?culties that t h i s  
may cause for registration authorities and for those who 
seek to market or purchase drugs that are inferior in 
terms of efficacy but cheaper. 
If a new drug shows efficacy in t h l s  phase, and is 
relatively free h-om adverse events, it should be granted 
full registration and a licence for appropriate clinical 
use. Such a licence should not disadvantage the new 
drug in comparison with drugs already licensed for 
similar indications. 
7.2.4 Phase IV 
During the marketing phase, which may overlap with 
phase 111, there should be long-term studies to establish 
the incidence of common and rare unwanted effects 
both on the patient (including drug interactions) and 
on commensal and pathogenic bacteria, and thus on the 
community as a whole. There should also be studies of 
patient-doctor concordance. The database for the new 
drug should be coordinated with other health-related 
databases, such as those related to disease incidence, 
antibiotic resistance, treatment patterns, health costs 
and, if possible, quality-of-life measures. 
It is recognized that such changes, developed only 
in outhe  here, are not Wrely to be made without cost, 
and it is suggested that this might be shared between 
those who develop drugs and those who benefit, includ- 
ing, potentially, patients and purchasers of health care. 
73 Conclusions 
Clinical development of antibiotics must evolve in the 
way that, for example, the preclinical sciences in the 
pharmaceutical industry have over the last 10 years. 
There have been major advances in combinatorial 
chemistry, proteomics, genomic screening and informa- 
tion technology, promising a plethora of new drugs. 
Since 1948 with the publication of the first prospective 
randomized clinical trials, there have been virtually no 
major advances in clinical evaluation. This lack of 
development in how to define precisely both drug 
value and appropriate use will seriously hamper the 
drug industry’s abihty to develop important new 
medicines discovered by new technologies. What is 
needed is h t h e r  but much more rapid development of 
conventional means of drug evaluation such as the 
clinical trial, as well as visionary use of new methods in 
epidemiology, and new use of electronic data merged 
in a way that identifies drug effects on both a popu- 
lation and an individual basis. 
Clearly, it will be necessary to persuade all the 
interested parties that change is necessary, and at the 
same time capable of answering their needs. The 
regulatory authorities have already shown a readiness to 
adapt, although moves away h-om the dominant role of 
the randomized, controlled trid might seem problematic 
if convincing alternatives are not perceived to be 
available. The participants in the conference on which 
t h i s  publication is based shared one hope at least for the 
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